To further explore the oncogenic role of CD90 in breast cancer, we undertook functional assays in two basal-like triple negative cell lines, the non-tumorigenic MCF10A line and the highly malignant Hs578T, by overexpressing CD90 in the former and CD90 knockdown in the latter. The gene discussed is THY1; the disease is breast cancer.